Literature DB >> 16540487

Recombinant tissue plasminogen activator injected into the vitreous cavity may penetrate the retinal veins of a porcine model of vascular occlusion.

T H Mahmoud1, Y-W Peng, A D Proia, M Davidson, V A Deramo, S Fekrat.   

Abstract

AIM: To determine if recombinant tissue plasminogen activator (rtPA) injected into the vitreous cavity can penetrate the retinal vessels of porcine eyes with or without vascular occlusion.
METHODS: Eight eyes (group I) of four pigs underwent clamping of the optic nerve flush with the globe for 90 minutes. One hour after reperfusion, one eye of each pig was injected with 75 microg of rtPA, and the fellow eye was injected with balanced salt solution (BSS). Eyes were processed for immunohistochemistry. Four additional eyes (group II) of two pigs were subjected to the same injections, but without optic nerve clamping.
RESULTS: After reperfusion, the clinical picture was similar to that of a central retinal vein occlusion. Immunoperoxidase staining showed rtPA only in the retinal veins but not the retinal arteries in all eyes injected with rtPA in both groups I and II. Those eyes also showed intense rtPA staining at the level of the internal limiting membrane (ILM). No staining was seen at the level of the ILM or inside the retinal vessels in the BSS injected eyes. Immunofluorescence staining showed intense staining at the level of the ILM, but not inside the retinal vessels in the rtPA-injected eyes.
CONCLUSIONS: rtPA may penetrate the retinal veins, but not the arteries of porcine eyes with and without vascular occlusion. The ILM may play a part in preventing rtPA penetration.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16540487      PMCID: PMC1857170          DOI: 10.1136/bjo.2005.089037

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  27 in total

1.  Evaluation of a commercial recombinant tissue-type plasminogen activator preparation in the subretinal space of the cat.

Authors:  J D Benner; L S Morse; C A Toth; M B Landers; L M Hjelmeland
Journal:  Arch Ophthalmol       Date:  1991-12

2.  Retinal surgery for treatment of central retinal vein occlusion.

Authors:  J N Weiss
Journal:  Ophthalmic Surg Lasers       Date:  2000 Mar-Apr

3.  A study of the ability of tissue plasminogen activator to diffuse into the subretinal space after intravitreal injection in rabbits.

Authors:  M Kamei; K Misono; H Lewis
Journal:  Am J Ophthalmol       Date:  1999-12       Impact factor: 5.258

4.  Intravitreal tissue plasminogen activator for acute central retinal vein occlusion.

Authors:  J M Lahey; D S Fong; J Kearney
Journal:  Ophthalmic Surg Lasers       Date:  1999-06

5.  Effect of intravitreal tissue plasminogen activator on experimental subretinal hemorrhage.

Authors:  G E Coll; J R Sparrow; A Marinovic; S Chang
Journal:  Retina       Date:  1995       Impact factor: 4.256

6.  Visual outcome after treatment with low-dose recombinant tissue plasminogen activator or hemodilution in ischemic central retinal vein occlusion.

Authors:  L O Hattenbach; G Wellermann; G W Steinkamp; I Scharrer; F H Koch; C Ohrloff
Journal:  Ophthalmologica       Date:  1999       Impact factor: 3.250

7.  Thrombolytic therapy for central retinal vein occlusion: results of a pilot study.

Authors:  M J Elman
Journal:  Trans Am Ophthalmol Soc       Date:  1996

8.  Treatment of central retinal vein occlusion by injection of tissue plasminogen activator into a retinal vein.

Authors:  J N Weiss
Journal:  Am J Ophthalmol       Date:  1998-07       Impact factor: 5.258

9.  Fibrinolytic therapy with low-dose recombinant tissue plasminogen activator in retinal vein occlusion.

Authors:  L O Hattenbach; G Steinkamp; I Scharrer; C Ohrloff
Journal:  Ophthalmologica       Date:  1998       Impact factor: 3.250

10.  Retinal toxicity of human tissue plasminogen activator in vitrectomized rabbit eyes.

Authors:  W D Irvine; M W Johnson; E Hernandez; K R Olsen
Journal:  Arch Ophthalmol       Date:  1991-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.